|
Editas Medicine公司宣布用于基因编辑的EDIT-101疗法进入临床试验!2018年11月30日,基因编辑公司Editas Medicine宣布,该公司开展使用CRISPR基因编辑技术治疗LCA10的临床试验获得FDA批准(Editas Medicine Announces FDA Acceptance of IND Application for EDIT-101)。该疗法可适用于遗传性视网膜衰退疾病Leber Congenital Amaurosis type 10(LCA10),该病症是由CEP290基因突变引起的单基因疾病。
EDIT-101是一个用于治疗LCA10疾病的基于基因编辑的实验药物,EDIT-101通过视网膜下注射给药,以将基因编辑系统直接输送到感光细胞中而达到治疗效果(EDIT-101 is a CRISPR-based experimental medicine under investigation for the treatment of Leber Congenital Amaurosis type 10 (LCA10). EDIT-101 is administered via a subretinal injection to reach and deliver the gene editing machinery directly to photoreceptor cells.)。
Editas Medicine 公司是在基因编辑领域处于领先的公司。Editas Medicine公司首席执行官Katrine Bosley说,FDA批准用于EDIT-101疗法的临床研究用的新药在基因编辑领域是一个重要时刻,重要的是对病人来讲是一个关键的里程碑,现在我们对于治疗LCA10更近了一步(“The FDA’s acceptance of our IND for EDIT-101 is a significant moment in the field of genome editing, and importantly, a critical milestone for patients, as we are now one step closer to a treatment for LCA10,”)。
CAMBRIDGE, Mass., Nov. 30, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application for EDIT-101, an experimental CRISPR genome editing medicine being investigated for the treatment of Leber Congenital Amaurosis type 10 (LCA10).
“The FDA’s acceptance of our IND for EDIT-101 is a significant moment in the field of genome editing, and importantly, a critical milestone for patients, as we are now one step closer to a treatment for LCA10,” said Katrine Bosley, President and Chief Executive Officer, Editas Medicine. “This moment is a truly exciting one for us, and we look forward to embarking on our next chapter as a clinical stage company, harnessing the power of CRISPR technology to transform the lives of people with serious diseases around the world.”
With the IND acceptance, Editas Medicine has earned a $25 million milestone payment from Allergan as part of the alliance between the companies to discover and develop experimental ocular medicines targeting serious, vision-threatening diseases. Editas Medicine and its partner, Allergan Pharmaceuticals International Limited (Allergan), a wholly-owned subsidiary of Allergan plc, expect to enroll 10 to 20 patients in a Phase 1/2 open label, dose escalation study to evaluate the safety, tolerability, and efficacy of EDIT-101.
About EDIT-101
EDIT-101 is a CRISPR-based experimental medicine under investigation for the treatment of Leber Congenital Amaurosis type 10 (LCA10). EDIT-101 is administered via a subretinal injection to reach and deliver the gene editing machinery directly to photoreceptor cells.
About Leber Congenital Amaurosis
Leber Congenital Amaurosis, or LCA, is a group of inherited retinal degenerative disorders caused by mutations in at least 18 different genes. It is the most common cause of inherited childhood blindness, with an incidence of two to three per 100,000 live births worldwide. Symptoms of LCA appear within the first years of life, resulting in significant vision loss and potentially blindness. The most common form of the disease, LCA10, is a monogenic disorder caused by mutations in the CEP290 gene and is the cause of disease in approximately 20‑30 percent of all LCA patients.
About The Editas Medicine-Allergan Alliance
In March 2017, Editas Medicine and Allergan Pharmaceuticals International Limited (Allergan) entered a strategic alliance and option agreement under which Allergan received exclusive access and the option to license up to five of Editas Medicine’s genome editing programs for ocular diseases, including EDIT-101. Under the terms of the agreement, Allergan is responsible for development and commercialization of optioned products, subject to Editas Medicine’s option to co-develop and share equally in the profits and losses of two optioned products in the United States. In August 2018, Allergan exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. Additionally, Editas Medicine exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States. Editas Medicine is also eligible to receive development and commercial milestones, as well as royalty payments on a per-program basis. The agreement covers a range of first-in-class ocular programs targeting serious, vision-threatening diseases based on Editas Medicine’s unparalleled CRISPR genome editing platform, including CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a).
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any
obligation to update any forward-looking statements, whether because of new information, future events or otherwise.
1/0 | 闂傚倸鍊搁崐鎼佸磹閹间礁纾归柟闂寸绾惧湱鈧懓瀚崳纾嬨亹閹烘垹鍊炲銈嗗笒椤︿即寮查鍫熲拺闁告繂瀚埢澶愭煕濡灝浜圭紒顔肩墦瀹曞ジ鎮㈢粙鍨紟婵犳鍠楅〃鍛涘Δ鍛闁挎洖鍊归悡銉︾節闂堟稒锛嶆俊鎻掓憸缁辨帡鎮╅悜妯煎涧婵烇絽娲ら敃顏呬繆閸洖妞介柛鎰ㄦ櫆閺嗕即姊绘担鍛婃儓闁归攱鍨圭槐鐐存媴閸撳弶缍庨梺鎯х箺椤鐣锋径鎰厪濠电偛鐏濋崝婊堟煟濠靛嫬鐏叉慨濠冩そ閹兘寮堕幐搴敤闂備胶鎳撻崵鏍箯閿燂拷:0 | 濠电姷鏁告慨鐑藉极閸涘﹥鍙忛柣鎴濐潟閳ь剙鍊块幐濠冪珶閳哄绉€规洏鍔戝鍫曞箣閻欏懐骞㈤梻鍌欐祰椤鐣峰Ο琛℃灃婵炴垶纰嶉浠嬫煏閸繃鍟掗柡鍐ㄧ墛閺呮煡鏌涘☉鍗炲箺婵炲牊鐓″铏圭矙濞嗘儳鍓板銈嗗灥椤﹂潧顕f繝姘櫜闁告稑鍊婚崰搴ㄥ煝鎼淬劌绠氱憸搴敊閸曨垱鐓涘璺烘濞呭棛绱掔拠鑼妞ゎ偄绻橀幖鍦喆閸曨偆锛忛梻渚€娼ф灙闁稿孩鐓¢幃鐢稿閵堝棌鎷洪梺鑽ゅ枑濠㈡ê鈻撻埡鍛厵闁告垯鍊栫€氾拷 | 濠电姷鏁告慨鐑藉极閸涘﹥鍙忛柣鎴f閺嬩線鏌熼梻瀵割槮缁炬儳顭烽弻锝夊箛椤掍焦鍎撻梺鎼炲妼閸婂潡寮诲☉銏╂晝闁挎繂妫涢ˇ銉х磽娴e搫小闁告濞婂濠氭偄閸忓皷鎷婚柣搴f暩鏋┑鈥茬矙濮婃椽宕崟顒€娅ょ紓浣筋嚙閻楁挸顕f繝姘╅柕澶堝灪閺傗偓闂備胶纭堕崜婵嬫晪缂備焦鍔栭惄顖氼潖濞差亜宸濆┑鐘插閻g兘鎮楅崗澶婁壕闂佸綊妫跨粈浣虹不閺嶃劋绻嗛柕鍫濆€告禍楣冩⒑鐎圭姵顥夋い锔诲灦閸┿垹顓奸崱妯肩Ф闂侀潧臎閸涱垰甯掔紓鍌氬€风粈渚€宕愰崫銉х煋闁圭虎鍠撻崑鎴澝归崗鍏肩稇闂佸崬娲弻锝夊棘閹稿孩鍎撻悗娈垮枟婵炲﹤顫忕紒妯诲闁惧繒鎳撶粭鈥斥攽閻愭彃绾ч柣妤冨Т閻g兘骞囬弶鎸庡祶濡炪倖鎸荤粙鎴炵閻愵剚鍙忔俊顖滃帶娴滈箖鎮楀鐐 | 闂傚倸鍊搁崐鎼佸磹閹间礁纾圭€瑰嫭鍣磋ぐ鎺戠倞鐟滃繘寮抽敃鍌涚厱妞ゎ厽鍨垫禍婵嬫煕濞嗗繒绠婚柡宀€鍠撶槐鎺楀閻樺磭浜紓鍌欒兌婵箖锝炴径鎰﹂柛鏇ㄥ灠缁犳盯鏌涢锝嗙妞ゅ骸绉瑰铏圭矙濞嗘儳鍓炬繛瀛樼矤娴滎亜顕g拠娴嬫闁靛繒濮堥妸锔轰簻闁哄倸鐏濈紞鏍ㄦ叏鐟欏嫷娈滈柟顔煎槻楗即宕ㄩ褎姣夐梺姹囧焺閸ㄩ亶銆冩繝鍌ゅ殨闁哄被鍎辩粻鐟懊归敐鍛础闁告瑥妫濆铏圭磼濡崵顦ラ梺绋匡工濠€閬嶅焵椤掍胶鍟查柟鍑ゆ嫹 |
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2025-3-18 08:26
Powered by ScienceNet.cn
Copyright © 2007-2025 中国科学报社